Case study on the use of intensive pediatric neurorehabilitation in the treatment of kernicterus

Jessie Mann, Dory A Wallace, Stephanie DeLuca, Jessie Mann, Dory A Wallace, Stephanie DeLuca

Abstract

Background: Kernicterus Spectrum Disorder (KSD) is the result of prolonged bilirubin toxicity resulting in widespread neurological injury. Once the bilirubin levels are normalized the encephalopathy becomes static, however the consequences of the injury can have life-long effects. The sequelae of KSD include motor impairments, auditory deficits, dental dysplasia, and potentially cognitive impairments. While KSD is a rare diagnosis, particularly in developed countries, there is evidence that there may be a global increase in incidence (Hansen, Semin Neonatol 7:103-9, 2002; Johnson, J Perinatol 29:S25-45, 2009; Kaplan etal. Neonatology 100:354-62, 2011; Maisels, Early Hum Dev 85:727-32, 2009; Olusanya etal., Arch Dis Child 99:1117-21, 2014; Steffensrud, Newborn Infant Nurs Rev 4:191-200, 2004). The literature on the treatment of various specific sequelae of KSD is varied, but in general specific therapeutic efforts to improve motor skills are not evidenced-based. The following is a case report on the use of Acquire therapy, an intensive neuromotor intervention, to ameliorate some of the motor-function deficits secondary to KSD.

Case presentation: This case-report presents the results of two intensive therapeutic intervention sessions in one male child with KSD. Treatments occurred at 28 and 34 months. The child presented with fine and gross motor deficits as well as communication delays. Each session consisted of daily therapy for 4 h each weekday for 3 weeks. The child was assessed before and after treatment with 2 standardized measures, the Gross Motor Function Measure (GMFM) and The Bayley Scales of Infant and Toddler Development (Bayley).

Conclusions: The GMFM at the 1st assessment was 34, 74at the 2nd assessment (after intervention 1), and 64 at the third assessment and 104 at the 4th assessment (after intervention 2). The Bayley at the 3rd assessment was 18, and 38 at the 4th assessment (after intervention 2).

Keywords: Intensive pediatric Neurorehabilitation; Kernicterus; Kernicterus Spectrum disorder.

Conflict of interest statement

Competing interestsThe authors declare that they have no competing interests.

© The Author(s). 2020.

Figures

Fig. 1
Fig. 1
The MR3 Cycle
Fig. 2
Fig. 2
Raw Score Change Standardized Assessments
Fig. 3
Fig. 3
Percent Change on Standardized Assessments
Fig. 4
Fig. 4
Goal Specific Measurement Changes
Fig. 5
Fig. 5
Percent Change on Goal Specific Measurements

References

    1. J-BL P, Riordan SM, Watchko J, Shapiro SM. The Neurological Sequelae of Neonatal Hyperbilirubinemia: Definitions, Diagnosis and Treatment of the Kernicterus Spectrum Disorders (KSDs) 2017.
    1. Shapiro SM, Bhutani VK, Johnson L. Hyperbilirubinemia and kernicterus. Clin Perinatol. 2006;33(2):387–410. doi: 10.1016/j.clp.2006.03.010.
    1. Bhutani VK, Vilms RJ, Hamerman-Johnson L. Universal bilirubin screening for severe neonatal hyperbilirubinemia. J Perinatol. 2010;30:S6–15. doi: 10.1038/jp.2010.98.
    1. Bhutani VK, Johnson LH, Jeffrey Maisels M, Newman TB, Phibbs C, Stark AR, et al. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol. 2004;24:650–662. doi: 10.1038/sj.jp.7211152.
    1. Watchko JF, Tiribelli C. Bilirubin-induced neurologic damage — mechanisms and management approaches. N Engl J Med. 2013;369(21):2021–2030. doi: 10.1056/NEJMra1308124.
    1. Usman F, Diala UM, Shapiro SM, Pichon JBL, Slusher TM. Acute bilirubin encephalopathy and its progression to kernicterus: current perspectives. Res Rep Neonatol. 2018; Available from: . [cited 2019 Jan 15].
    1. Hansen TWR. Kernicterus: an international perspective. Semin Neonatol. 2002;7(2):103–109. doi: 10.1053/siny.2002.0118.
    1. Johnson L, Bhutani VK, Karp K, Sivieri EM, Shapiro SM. Clinical report from the pilot USA kernicterus registry (1992 to 2004) J Perinatol. 2009;29:S25–S45. doi: 10.1038/jp.2008.211.
    1. Kaplan M, Bromiker R, Hammerman C. Severe neonatal Hyperbilirubinemia and kernicterus: are these still problems in the third millennium? Neonatology. 2011;100(4):354–362. doi: 10.1159/000330055.
    1. Maisels MJ. Neonatal hyperbilirubinemia and kernicterus — not gone but sometimes forgotten. Early Hum Dev. 2009;85(11):727–732. doi: 10.1016/j.earlhumdev.2009.09.003.
    1. Olusanya BO, Ogunlesi TA, Slusher TM. Why is kernicterus still a major cause of death and disability in low-income and middle-income countries? Arch Dis Child. 2014;99(12):1117–1121. doi: 10.1136/archdischild-2013-305506.
    1. Steffensrud S. Hyperbilirubinemia in term and near-term infants: kernicterus on the rise? Newborn Infant Nurs Rev. 2004;4(4):191–200. doi: 10.1053/j.nainr.2004.09.001.
    1. Shapiro SM. Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND) J Perinatol. 2005;25(1):54–59. doi: 10.1038/sj.jp.7211157.
    1. Deluca SC, Echols K, Law CR, Ramey SL. Intensive pediatric constraint-induced therapy for children with cerebral palsy: randomized, controlled, crossover trial. J Child Neurol. 2006;21(11):931–938. doi: 10.1177/08830738060210110401.
    1. DeLuca SC, Echols K, Ramey SL, Taub E. Pediatric constraint-induced movement therapy for a young child with cerebral palsy: two episodes of care. Phys Ther. 2003;83(11):1003. doi: 10.1093/ptj/83.11.1003.
    1. DeLuca SC, Ramey SL, Trucks MR, Wallace DA. Multiple Treatments of Pediatric Constraint-Induced Movement Therapy (pCIMT): A clinical cohort study. Am J Occup Ther Off Publ Am Occup Ther Assoc. 2015;69(6):6906180010p1. doi: 10.5014/ajot.2015.019323.
    1. DeLuca SC, Wallace DA, Trucks MR, Mukherjee K. A clinical series using intensive neurorehabilitation to promote functional motor and cognitive skills in three girls with CASK mutation. BMC Res Notes. 2017;10(1):743. doi: 10.1186/s13104-017-3065-z.
    1. DeLuca S, Echols K, Ramey SL. (Ed.) ACQUIREc therapy: a training manual for effective application of pediatric constraint-induced movement therapy. Hillsborough, NC: Mindnurture; 2007.
    1. Rosenbaum PL, Walter SD, Hanna SE, Palisano RJ, Russell DJ, Raina P, et al. Prognosis for gross motor function in cerebral palsy: creation of motor development curves. JAMA. 2002;288(11):1357–1363. doi: 10.1001/jama.288.11.1357.
    1. Russell DJ, Rosenbaum PL, Wright M, Avery LM. Gross motor function measure (GMFM-66 & GMFM-88) user’s manual. London: Mac Keith Press; 2002.
    1. Albers CA, Grieve AJ. Test review: Bayley, N. (2006). Bayley scales of infant and toddler development– third edition. San Antonio, TX: Harcourt assessment. J Psychoeduc Assess. 2007;25(2):180–190. doi: 10.1177/0734282906297199.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する